- Conditions
- Nutrition, Healthy
- Interventions
- Carbohydrate Dissolvable Strip, Carbohydrate Mouth Rinse, Water Mouth Rinse
- Other
- Lead sponsor
- University of Georgia
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Athens, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Short Bowel Syndrome
- Interventions
- Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection
- Drug · Procedure · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Kidney Disease; Iron Deficiency Anemia
- Interventions
- Ferumoxytol, Iron sucrose
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 8
- States / cities
- Hollywood, Florida • Detroit, Michigan • Kansas City, Missouri + 5 more
- Conditions
- Iron Deficiency Anemia
- Interventions
- ferumoxytol, Iron sucrose
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Gainesville, Florida • Miami, Florida + 2 more
- Conditions
- Leishmaniasis
- Interventions
- GLA-SE, LEISH-F3, MPL-SE, SE
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Norovirus
- Interventions
- Adjuvant/Excipients, placebo, Norwalk VLP Vaccine
- Drug · Device · Biological
- Lead sponsor
- LigoCyte Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 1 more
- Conditions
- Cmv Congenital, CMV, Congenital Cmv, SNHL, Sensorineural Hearing Loss
- Interventions
- Valganciclovir, Simple Syrup
- Drug
- Lead sponsor
- Albert Park
- Other
- Eligibility
- 1 Month to 12 Months
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 30
- States / cities
- Palo Alto, California • San Diego, California • San Francisco, California + 25 more
- Conditions
- Acute Gastroenteritis, Norwalk Virus Infection
- Interventions
- Norwalk VLP vaccine, mannitol and sucrose, Norwalk virus
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas
- Conditions
- Melanoma, Unresectable Melanoma
- Interventions
- Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boston, Massachusetts • New York, New York
- Conditions
- Neoplasms, Breast
- Interventions
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Placebo, Aromatase inhibitor, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Trastuzumab
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 8
- States / cities
- Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more